Cancer and ageing
Human evidence and active trials are visible in this field
515 human-evidence records · 160 active trials · 560 visible funding records · 6,594 universities
Australian Patent Application
Inhibition of endogenous reverse transcriptase and targeting of cells for prophylaxis and therapy of cancer and aging
Source-linked patent metadata for Inhibition of endogenous reverse transcriptase and targeting of cells for prophylaxis and therapy of cancer and aging, including priority, record stage and longevity-topic connections.
Australian application snapshot
Patent application record
This privacy-minimal view describes one official Australian patent application record. It is not presented as a complete worldwide patent family.
- Application number
- AU2018210001
- Earliest priority
- January 23, 2017
- Application date
- July 17, 2019
- Source record
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Why names are absent
This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.
Topics connected by metadata
Cancer and ageing82% metadata match
How the patent office classifies this invention
C12N7/00 · C12Q1/70
Verify in the original patent source →